Growth Arrest-Specific Factor 6 (GAS6) Is Increased in COVID-19 Patients and Predicts Clinical Outcome
Authors:
- Albert MoralesAlbert Morales
- Silvia Rojo RelloSRSilvia Rojo Rello
- Helena CristóbalHCHelena Cristóbal
- Aida Fiz-LópezAida Fiz-López
- Elisa ArribasEAElisa Arribas
- Montserrat MaríMontserrat Marí
- Anna TutusausATAnna Tutusaus
- Paloma de la Cal-SabaterPCPaloma de la Cal-Sabater
- Gerry A.F. NicolaesGNGerry A.F. Nicolaes
- José T. Ortiz-PérezJOJosé T. Ortiz-Pérez
- David BernardoDBDavid Bernardo
- Pablo García de FrutosPablo García de Frutos
Open Access
- 26 March 2021
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 9 (4) , 335
Abstract
Background: Growth arrest-specific factor 6 (GAS6) and the Tyro3, AXL, and MERTK (TAM) receptors counterbalance pro-inflammatory responses. AXL is a candidate receptor for SARS-CoV-2, particularly in the respiratory system, and the GAS6/AXL axis is targeted in current clinical trials against COVID-19. However, GAS6 and TAMs have not been evaluated in COVID-19 patients at emergency admission. Methods: Plasma GAS6, AXL, and MERTK were analyzed in 132 patients consecutively admitted to the emergency ward during the first peak of COVID-19. Results: GAS6 levels were higher in the SARS-CoV-2-positive patients, increasing progressively with the severity of the disease. Patients with initial GAS6 at the highest quartile had the worst outcome, with a 3-month survival of 65%, compared to a 90% survival for the rest. Soluble AXL exhibited higher plasma concentration in deceased patients, without significant differences in MERTK among SARS-CoV-2-positive groups. GAS6 mRNA was mainly expressed in alveolar cells and AXL in airway macrophages. Remarkably, THP-1 human macrophage differentiation neatly induces AXL, and its inhibition (bemcentinib) reduced cytokine production in human macrophages after LPS challenge. Conclusions: Plasma GAS6 and AXL levels reflect COVID-19 severity and could be early markers of disease prognosis, supporting a relevant role of the GAS6/AXL system in the immune response in COVID-19.Keywords
Funding Information
- Ministerio de Ciencia e Innovación (RTI2018-095672-B-I00)
- Instituto de Salud Carlos III (PI15/00531, PI19/01410)
- Fundació la Marató de TV3 (20153030 and 20153031)
- European Commission (ERDF “A way to make Europe”)
- Consejo Superior de Investigaciones Científicas (CSIC-COV19-016/202020E155)
- Junta de Castilla y León (07.04.467B04.74011.0)
- CERCA Programme/Generalitat de Catalunya (AGAUR 2017_SGR_177)
This publication has 30 references indexed in Scilit:
- Axl Receptor Axis: A New Therapeutic Target in Lung CancerJournal of Thoracic Oncology, 2016
- Gas6/Axl pathway is activated in chronic liver disease and its targeting reduces fibrosis via hepatic stellate cell inactivationJournal of Hepatology, 2015
- Tissue-based map of the human proteomeScience, 2015
- AXL receptor tyrosine kinase is increased in patients with heart failureInternational Journal of Cardiology, 2014
- Growth arrest-specific gene 6 (Gas6) levels are elevated in patients with chronic renal failureNephrology Dialysis Transplantation, 2012
- The Tyro3 Receptor Kinase Axl Enhances Macropinocytosis of Zaire EbolavirusJournal of Virology, 2011
- Plasma concentrations of Gas6 (growth arrest specific protein 6) and its soluble tyrosine kinase receptor sAxl in sepsis and systemic inflammatory response syndromesCritical Care, 2010
- Gas6 promotes inflammation by enhancing interactions between endothelial cells, platelets, and leukocytesBlood, 2008
- Vitamin K‐Dependent Actions of Gas62008
- Elevated growth-arrest-specific protein 6 plasma levels in patients with severe sepsisCritical Care Medicine, 2006